Medivir Q1 2025: Calm Quarter Awaiting Phase IIb
Idag, 08:34
Idag, 08:34
Redeye comments on Medivir's Q1 report, during which the main events were the completion of the phase IIa study of fostrox in combination with Lenvima and the licensing deal signed by Medivir's partner Infex in India.
Idag, 08:34
Redeye comments on Medivir's Q1 report, during which the main events were the completion of the phase IIa study of fostrox in combination with Lenvima and the licensing deal signed by Medivir's partner Infex in India.
Rapportperioden
Placera granskar fondjättarna
Analytikerna om Volvo Cars
Analys
Rapportperioden
Placera granskar fondjättarna
Analytikerna om Volvo Cars
Analys
OMX Stockholm 30
1 DAG %
Senast
2 434,06